Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
作者信息
Nishida Naoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
Abstract
摘要
相似文献
1
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
2
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
3
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".预测晚期肝细胞癌组织中联合免疫治疗反应的转录组特征：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
4
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".对关于“预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信的回复
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
5
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
6
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
7
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".致编辑的信：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
8
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
9
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.阿替利珠单抗联合贝伐单抗作为不可切除肝细胞癌的一线治疗：IIIb期AMETHISTA试验的中期分析结果
ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27.
10
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.阿替利珠单抗联合贝伐单抗用于不符合IMbrave150纳入标准的不可切除肝细胞癌患者的早期反应及安全性
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
引用本文的文献
1
Advancing the management of hepatocellular carcinoma: surrogate markers and predictive biomarkers for survival on immunotherapy.推进肝细胞癌的管理：免疫治疗生存的替代标志物和预测生物标志物
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):311-315. doi: 10.21037/hbsn-2025-78. Epub 2025 Mar 25.
2
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".肉瘤样肝细胞癌的遗传学见解：ARID2在发病机制和免疫特征中的关键作用：关于“肉瘤样肝细胞癌的综合分子特征”的社论
Clin Mol Hepatol. 2025 Apr;31(2):635-639. doi: 10.3350/cmh.2025.0071. Epub 2025 Jan 24.
3
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
本文引用的文献
1
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
2
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.纳武利尤单抗联合伊匹单抗治疗索拉非尼治疗后晚期肝细胞癌患者：CheckMate 040 的 5 年结果。
Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22.
3
Biomarkers for immunotherapy of hepatocellular carcinoma.用于肝细胞癌免疫治疗的生物标志物。
Nat Rev Clin Oncol. 2023 Nov;20(11):780-798. doi: 10.1038/s41571-023-00816-4. Epub 2023 Sep 19.
4
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.肿瘤生物学和免疫浸润定义了与免疫治疗后总体生存相关的原发性肝癌亚群。
Cell Rep Med. 2023 Jun 20;4(6):101052. doi: 10.1016/j.xcrm.2023.101052. Epub 2023 May 23.
5
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
6
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.炎症和非炎症 HCC 分类：一种修正的免疫基因组分类。
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.
7
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.中性粒细胞与淋巴细胞比值可预测接受阿替利珠单抗联合贝伐单抗治疗的不可切除肝细胞癌患者的早期预后：一项多中心分析。
Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):698-706. doi: 10.1097/MEG.0000000000002356. Epub 2022 Feb 14.
8
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.高循环细胞毒性 T 细胞和肿瘤内免疫特征的肝细胞癌患者从 pembrolizumab 中获益：来自单臂 2 期试验的结果。
Genome Med. 2022 Jan 6;14(1):1. doi: 10.1186/s13073-021-00995-8.
9
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.免疫微环境可预测接受抗PD-1抗体治疗的肝细胞癌患者的生存情况。
Liver Cancer. 2021 Jul;10(4):380-393. doi: 10.1159/000516899. Epub 2021 Jun 9.
10
Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma.致癌通路在肝癌免疫抑制微环境中的作用及其临床意义
Cancers (Basel). 2021 Jul 21;13(15):3666. doi: 10.3390/cancers13153666.
Zotero 插件